



## Biocept to Hold Business Update Conference Call on August 30, 2023

Aug 25, 2023

SAN DIEGO--(BUSINESS WIRE)--Aug. 25, 2023-- [Biocept, Inc.](#) (Nasdaq: BIOC) management will hold a conference call on August 30, 2023, beginning at 4:00 p.m. Eastern time (1:00 p.m. Pacific time) to provide a business update and to answer questions.

Participants can pre-register for the conference call [here](#). Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time.

The conference call can be accessed at the time of the live call by dialing (855) 656-0927 for domestic callers, (855) 669-9657 for Canadian callers or (412) 902-4109 for other international callers. A live webcast of the conference call will be available on the investor relations page of the Company's website at <http://ir.biocept.com/events.cfm>.

A replay of the call will be available for 48 hours following its conclusion and can be accessed by dialing (877) 344-7529 for domestic callers, (855) 669-9658 for Canadian callers or (412) 317-0088 for other international callers. Please use event passcode 4959663. A replay of the webcast will be available for 90 days.

### About Biocept

Biocept is a molecular diagnostics company with commercialized assays for patients with carcinomas or melanomas. Our experts have spent years working to change the way physicians look at cerebrospinal fluid in cancer patients. Biocept has developed a unique, patented methodology to isolate cancer material that is shed from the primary tumor, such as CSF tumor cells (CSF-TCs) and cell-free DNA (cfDNA). As such, Biocept is a leading commercial provider of testing services designed to enable clinicians to rapidly detect and monitor cancer biomarkers from a cerebrospinal fluid sample.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20230825496855/en/): <https://www.businesswire.com/news/home/20230825496855/en/>

### Investor & Media Contact:

LHA Investor Relations

Jody Cain

[Jcain@lhai.com](mailto:Jcain@lhai.com), (310) 691-7100

Source: Biocept, Inc.